Dr Curtis Dobson has won the Commercial Innovator of the Year award at the BBSRC’s Fostering Innovation Awards 2014. The awards were presented in London, in front of a prestigious audience featuring leading figures from the worlds of investment, industry, government, charity, and academia. He scooped the £15,000 award in recognition of two successful healthcare companies that are based on his research.
Ai2 Ltd has developed anti-infective peptide technology for use in ophthalmics and medical devices. This technology helps to reduce infections caused by contact lenses, catheters, wound dressings, and orthopaedic devices. Microsensor Ltd is developing a new approach to the early detection of medical device infection and environmental monitoring. The technology is simple, inexpensive, and robust, proving a clear indication of clinically or industrially relevant levels of infection on a surface. Dr Curtis Dobson said:
“Being recognised by this BBSRC award is a privilege and an honour, and further validates our efforts to tackle resistant infection, which impacts so many people throughout the UK and beyond. The additional funds will help us accelerate commercialisation of our latest technologies, ultimately delivering benefits to patients sooner.”
Professor Ian Kimber, Faculty Associate Dean for Business Development, said:
“This is a remarkable achievement and is a testament to the industry and innovation of Curtis and his co-workers. It is a reflection also of the emphasis we place on ensuring that the fruits of our substantial investment in research deliver valuable products and opportunities.”